The use of tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, in EGFR-mutant lung adenocarcinoma patients successfully causes tumor regression and prolonged patient survival; [6] however, drug resistance and tumor relapse eventually occur. The gene discussed is EGFR; the disease is neoplasm.